PenderFund Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

PenderFund Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-233,590	Closed	-$684K	–	132
2023 Q2	$684K	Buy	+233,590	New	+$484K	0.21%	71

PenderFund Capital Management's PRTK Position: Q3 2023 in Review

PenderFund Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 233,590 shares — an estimated $684K sold.

PenderFund Capital Management first reported a position in PRTK in Q2 2023 and held it in 1 quarter. The position peaked at $684K in Q2 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

PenderFund Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
PenderFund Capital Management sold 233,590 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $684K.
PenderFund Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
PenderFund Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $684K in Q2 2023.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on PenderFund Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.